Cognetivity Neurosciences Sees Scientific Paper Outline Strong Use-Case For Integrated Cognitive Assessment Test

Cognetivity Neurosciences (CSE: CGN) this morning announced that it has seen another publication of a scientific paper on its assessment tool for early-stage Alzheimer’s. Referred to by the company as an Integrated Cognitive Assessment, or ICA, the firm indicates that the peer-reviewed paper provides further evidence of the benefits of the tool.

The paper itself reportedly demonstrates the “sensitivity to early-stage Alzheimer’s Disease, freedom from cultural or educational bias and suitability for remote patient monitoring,” that the assessment tool offers. Furthermore, it further validates the use of the tool as a digital cognitive biomarker, which is effective at identifying mild cognitive impairment and Alzheimer’s disease, particularly at mild or early stages.

One of the key benefits of the ICA, as outlined within the scientific paper, is that the platform performs consistently in international populations, where traditionally there have been limitations due to language and culture-specific data. The result is that the tool can be effectively deployed at scale rapidly, without the need to collect additional data.

Lastly, it was also highlighted that the tool works excellent as a remote cognitive assessment, without the loss of testing accuracy. This feature in particular makes the platform an excellent option for high-frequency monitoring both at clinics and at home.

The diagnostic accuracy of the ICA and its novel use of explainable AI, combined with the power to generalize across other languages and cultures, make it uniquely suitable for cognitive screening across large and diverse populations. And in light of the FDA’s recent approval of the disease-modifying drug aducanumab, the need for a device capable of screening a wide population of at-risk individuals has never been higher.

Professor Dag Aarsland, co-author of the scientific paper

The full scientific paper can be reviewed here.

Cognetivity Neurosciences last traded at $1.07 on the CSE.


FULL DISCLOSURE: Cognetivity Neurosciences Ltd is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Cognetivity Neurosciences Ltd on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Video Articles

Gold Is Now Smart Money’s End Game | Doug Casey

Is Gold’s Bull Market About to Hit Junior Stocks? | Ken Armstrong – Westhaven Gold

Surge Battery Metals: The Nevada North Lithium PEA

Recommended

Goliath Resources Closes Out Funding Round With Total Gross Proceeds Of $27.1 Million

Silver47 Kickstarts 4,000 Metre Drill Campaign At Red Mountain Project

Related News

Early Detection For Alzheimer’s Via AI Driven Cognitive Testing – The Daily Dive feat Thomas Sawyer

Joining us at the midpoint of the week on the Daily Dive, is that of...

Wednesday, January 27, 2021, 01:30:00 PM

Cognetivity Neurosciences Sees Granting Of FDA Clearance For Cognitive Assessment Tool

Cognetivity Neurosciences (CSE: CGN) has reached a major achievement. The company has been granted FDA...

Wednesday, October 20, 2021, 09:22:23 AM

Cognetivity Sees Its Cognitive Tool Used In Clinical Study For OCD

While it may have been initially developed for the early detection of Alzheimer’s disease or...

Tuesday, September 13, 2022, 08:38:28 AM

Cognetivity: Echelon Raises Price Target To $1.50 After Biogen Approval

Monday was a very big day for companies who are in the business to help...

Wednesday, June 9, 2021, 11:22:00 AM

Cognetivity To Deploy Flagship Assessment Tool At Florida-Based Clinic

The rollout of Cognetivity Neurosciences’ (CSE: CGN) flagship product, the CognICA cognitive assessment tool, continues....

Wednesday, May 25, 2022, 07:53:15 AM